Depletion of insulin receptor substrate 2 reverses oncogenic transformation induced by v-src

Acta Pharmacol Sin. 2011 May;32(5):611-8. doi: 10.1038/aps.2011.18. Epub 2011 May 2.

Abstract

Aim: To investigate the role of insulin receptor substrate 2 (IRS-2) in oncogenic transformation induced by v-src.

Methods: IRS-2 gene was silenced using small interfering RNAs (siRNAs). Nuclear translocation and interaction of IRS-2 with v-src was determined using subcellular fractionation, confocal microscopy, and immunoprecipitation. The activity of the cyclin D1 promoter and r-DNA promoter was measured with a luciferase assay.

Results: Depletion of IRS-2 inhibited R-/v-src cell growth and reverse the oncogenic transformation. IRS-2 bound to src via its two PI3-K binding sites, which are critical for activities involved in the transformation. Nuclear IRS-2 occupied the cyclin D1 and rDNA promoters. The combination of IRS-2 and v-src increased the activity of the two promoters, especially the rDNA promoter.

Conclusion: Depletion of insulin receptor substrate 2 could reverse oncogenic transformation induced by v-src.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3 Cells
  • Animals
  • Binding Sites
  • Cell Line, Tumor
  • Cells, Cultured
  • DNA, Ribosomal / metabolism
  • Fibroblasts / metabolism*
  • Gene Silencing
  • Insulin Receptor Substrate Proteins / genetics
  • Insulin Receptor Substrate Proteins / metabolism*
  • Mice
  • Oncogene Protein pp60(v-src) / metabolism*
  • Phosphatidylinositol 3-Kinases / metabolism
  • Promoter Regions, Genetic
  • RNA, Small Interfering / administration & dosage
  • Receptor, IGF Type 1 / genetics

Substances

  • DNA, Ribosomal
  • IRS2 protein, human
  • Insulin Receptor Substrate Proteins
  • Irs2 protein, mouse
  • RNA, Small Interfering
  • Phosphatidylinositol 3-Kinases
  • Receptor, IGF Type 1
  • Oncogene Protein pp60(v-src)